title: Structure-function relationship of basic fibroblast growth factor: site-directed mutagenesis of a putative heparin-binding and receptor-binding region.
abstract: Basic residues Arg-118, Lys-119, Lys-128, and Arg-129 within a putative heparin-binding and receptor-binding region of the 155-amino acid form of basic fibroblast growth factor (bFGF) have been changed to neutral glutamine residues by site-directed mutagenesis of the human bFGF cDNA. The bFGF mutant (M6B-bFGF) was expressed in E. coli and purified to homogeneity. When compared to wild type bFGF, M6B-bFGF showed in cultured endothelial cells a similar receptor-binding capacity and mitogenic activity, but a reduced affinity for heparin-like low affinity binding sites, a reduced chemotactic activity, and a reduced capacity to induce the production of urokinase-type plasminogen activator. In vivo, M6B-bFGF lacked a significant angiogenic activity. Modifications of both the primary and the tertiary structure of bFGF appear to be responsible for the modified biological properties of M6B-bFGF, thus confirming the possibility to dissociate at the structural level some of the biological activities exerted by bFGF on endothelial cells.
authors.affiliation: Department of Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Presta
authors.forename: M
authors.initials: M
authors.lastname: Statuto
authors.forename: A
authors.initials: A
authors.lastname: Isacchi
authors.forename: P
authors.initials: P
authors.lastname: Caccia
authors.forename: A
authors.initials: A
authors.lastname: Pozzi
authors.forename: A
authors.initials: A
authors.lastname: Gualandris
authors.forename: M
authors.initials: M
authors.lastname: Rusnati
authors.forename: L
authors.initials: L
authors.lastname: Bergonzoni
authors.forename: P
authors.initials: P
authors.lastname: Sarmientos
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D001665:Binding Sites; D001667:Binding, Competitive; D002417:Cattle; D002455:Cell Division / Q000187:drug effects; D002461:Cell Line, Transformed; D002462:Cell Membrane / Q000378:metabolism; D002633:Chemotaxis / Q000187:drug effects; D003001:Cloning, Molecular; D004730:Endothelium, Vascular; D004790:Enzyme Induction; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology*; D006493:Heparin / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D009389:Neovascularization, Pathologic; D009838:Oligodeoxyribonucleotides; D010957:Plasmids; D010960:Plasminogen Activators / Q000096:biosynthesis; D011956:Receptors, Cell Surface / Q000378:metabolism*; D017468:Receptors, Fibroblast Growth Factor
chemical_list: D009838:Oligodeoxyribonucleotides; D011956:Receptors, Cell Surface; D017468:Receptors, Fibroblast Growth Factor; D016222:Fibroblast Growth Factor 2; D006493:Heparin; D010960:Plasminogen Activators